Article | August 16, 2021

Implementing GMP For Early-Phase Development With Cartesian Therapeutics Co-Founder And CEO, Dr. Murat Kalayoglu

Source: Cytiva

A key factor in the success of a developing drug or therapy is the success of early clinical trials. A focus on Good Manufacturing Practice (GMP) standards for phase 1, first-in-human trials is critical to maximize the chances of success from a project’s start. For cell therapy development, where even small errors can make a big difference, it’s even more important.

Dr. Murat Kalayoglu, Co-Founder and CEO of Cartesian Therapeutics, has observed how regulatory and GMP standards have evolved over the years throughout her career.  Cartesian is a fully integrated, clinical-stage biopharmaceutical company developing novel cell and gene immunotherapies. Dr. Kalayoglu was previously CEO of Topokine Therapeutics, acquired by Allergan in 2016.

Dr. Kalayoglu recently sat down with The Business of Biotech podcast to talk about how the cell therapy space should approach phase 1 clinical trials, from raw material management to interpreting guidance and early-stage manufacturing.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online